Reported Q4 2025 net loss of $20.9M ($0.27/share) vs. $25.9M ($0.78/share) in Q4 2024; FY 2025 net loss of $100.0M ($1.86/share) vs. $98.3M ($3.09/share) in FY 2024. Cash, cash equivalents, and investments totaled $246.6M at 12/31/2025, expected to fund operations into 2028. LX2006 (FA cardiomyopathy): Registrational SUNRISE-FA 2 open-label pivotal protocol and SAP submitted to FDA in Q1 2026 following a Type B meeting; FDA feedback expected Q2 2026; study initiation on track for 1H 2026. FDA CDRP meeting in March 2026 aligned on flexible CMC validation for LX2006, including potential reduced PPQ runs and concurrent validation; commercial readiness efforts underway to support BLA. Updated LX2006 interim data presented at ACC (March 2026): sustained or deepening improvements in cardiac and neurologic measures including statistically significant mFARS improvement vs. propensity-matched natural history controls; generally well tolerated with no Grade 3+ SAEs to date. LX2020 (PKP2-ACM): Interim Phase I/II data show dose-dependent increases in PKP2 expression and reductions in arrhythmia burden in high-dose cohorts; generally well tolerated across 10 participants with no clinically significant complement activation. Corporate: Entered research collaboration with Johnson & Johnson on targeted cardiac AAV delivery; appointed Narinder Bhalla, MD, as Chief Medical Officer; completed $154M equity financing in October 2025.